UNIVERSITY OF SOUTH FLORIDA

Silmitasertib (CX-4945), a CK2 inhibitor, shows anticancer activity in various tumors and is being tested in early human trials for cholangiocarcinoma, basal cell carcinoma, medulloblastoma, and neuroblastoma. It enhances anticancer activity when combined with DNA-damaging chemotherapy drugs and is also being tested for severe Covid-19 symptoms, reducing cytokine storm and improving recovery times.

Senhwa Biosciences enrolls first patient in Phase I/II study of Silmitasertib combined with chemotherapy for relapsed or refractory solid tumors in children and young adults, aiming to establish a recommended dose and assess safety, tolerability, and efficacy, with a focus on neuroblastoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma.

At the NCODA Fall Summit, Moffitt Cancer Center panelists discussed treating stage 3A lung adenocarcinoma, emphasizing genetic testing, adjuvant immunotherapy, targeted treatments, insurance challenges, and multidisciplinary care. A case study highlighted the importance of NGS, ALK gene fusion detection, and a multidisciplinary approach involving nurse navigators, medical oncologists, molecular pathologists, and pharmacists.

The 1984 College of Medicine, University of Lagos alumni inaugurated a $2m endowment fund, donated a renewable power structure, and renovated facilities to support academic excellence and infrastructure development. They also visited Heart of Gold Children Hospital, impacting 72 abandoned children. The alumni emphasized the need for more funds and called on Nigerian youths to contribute to national development.

Dupilumab significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) uncontrolled by H1-antihistamines, according to the phase III LIBERTY-CUPID study C. Dupilumab showed an 8.64-point reduction in itch severity and a 15.86-point reduction in urticaria activity severity compared to placebo. The study supports regulatory resubmission in the U.S. for dupilumab as a targeted therapy for CSU.

Dupixent (dupilumab) significantly reduced itch and urticaria activity scores in biologic-naive CSU patients on antihistamines, with 41% achieving well-controlled disease vs. 23% on placebo. Safety profile consistent with known dermatological indications.

GLP-1 drugs like Wegovy and Zepbound are replacing bariatric surgery for obesity treatment, causing a 25.6% drop in surgeries. This shift raises questions about the future of surgical programs and the long-term impact on obesity care.

Dupixent phase 3 LIBERTY-CUPID Study C results show significant reduction in itch and urticaria activity scores, with higher disease control rates in chronic spontaneous urticaria patients on antihistamines, to be presented at ACAAI 2024.

Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive Phase 3 LIBERTY-CUPID Study C data support potential U.S. regulatory resubmission by year-end, aiming for Dupixent to be the first new targeted treatment for CSU in over 10 years.

FDA approves AbbVie's Vyalev (foscarbidopa and foslevodopa) for advanced Parkinson’s disease, offering the first subcutaneous, 24-hour levodopa-based infusion in the US. Vyalev aims to manage motor fluctuations and dyskinesia, with a Phase III trial showing increased 'on' time without dyskinesia. Adverse reactions are mild to moderate, and coverage for Medicare patients is expected in 2025.